Form 4: Tonix Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
James Treco, a director of Tonix Pharmaceuticals, reported the acquisition of stock options in a recent SEC filing.
Summary
- James Treco, a director at Tonix Pharmaceuticals Holding Corp., filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on May 13, 2025.
- Treco acquired 10,000 stock options with an exercise price of $20.18.
- These options vest on the earlier of the one-year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders and expire on May 13, 2035.
- Treco also directly owns 10,000 shares of Tonix Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 05/13/2025 | Date of the stock option transaction. |
| 05/13/2026 | Earliest vesting date for the stock options (one year anniversary of grant date). |
| 05/13/2035 | Expiration date of the stock options. |
Keywords
Form 4, stock options, TNXP, Tonix Pharmaceuticals, insider trading, James Treco, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.